

#9
Eloc. / Amtd. B
9/20/02
2/003

Attorney Docket No. 54099.8003.US01

I hereby certify that this correspondence is being transmitted via facsimile to TC1600 at the United States Patent and Trademark Office at (703) 872-9306, on:

Date: August 22, 2002By: Jennifer L. Mahoney
Jennifer L. Mahoney

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Allan, *et al.*

APPLICATION NO.: 09/722,109

FILED: January 26, 2001

FOR: HIGH LEVEL CYTOKINE PRODUCTION
WITH ENHANCED CELL VIABILITY

EXAMINER: U. Winkler

ART UNIT: 1648

CONF. No: 8965

Amendment in Response to Restriction RequirementAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated March 22, 2002, please amend the application as follows.

In the Claims

Please cancel claims 9-10, 13-24, 27-28, 35-36, without prejudice.

Please replace claims 8, 11, 26, 29, 34, and 37, with the following substitute claims:

8. (Twice Amended) The human cell line according to claim 7, wherein priming means exposing said modified cells to phorbol myristate acetate (PMA).